Skip to main content

Table 2 Results of primary outcomes by gestational age subgroup[33]

From: Magnesium sulphate at 30 to 34 weeks’ gestational age: neuroprotection trial (MAGENTA) - study protocol

Trial

N

Eligible (GA wks)

DEATH or CP

CP

DEATH

 

RR, 95% CI

RR, 95% CI

RR, 95% CI

MagNetǂ [43]

59

>24 to <34

4.83, 0.60 to 38.90

6.77, 0.37 to 125.65

1.93, 0.19 to 20.18

Marret[46]

688

viable to <33

0.80, 0.58 to 1.10

0.70, 0.41 to 1.19

0.85, 0.55 to 1.32

Rouse[44]

2444

24 to <32

0.90, 0.73 to 1.10

0.59, 0.40 to 0.85*

1.13, 0.87 to 1.48

Crowther[45]

1255

<30

0.82, 0.66 to 1.02

0.85, 0.55 to 1.31

0.81, 0.62 to 1.05

Overall

4446

viable to <34

0.85, 0.75 to 0.98*

0.71, 0.55 to 0.91*

0.95, 0.80 to 1.12

  1. ǂ Neuroprotective arm; CP cerebral palsy; GA gestational age; * statistically significant.